Eurofins Panlabs, Inc. v. Ricerca Biosciences, LLC, et al., C.A. No. 8431-VCN (May 30, 2014) (Noble, V.C.)
By David Bernstein and Marisa DiLemme
The decision in Eurofins Panlabs, Inc. v. Ricerca Biosciences, LLC concerns a Stock and Asset Purchase Agreement (the “SAPA”) entered into in September 2012 by plaintiff, Eurofins Panlabs, Inc. (“Eurofins”), a Delaware corporation, and defendants, Ricerca Biosciences, LLC (“Ricerca”), a Delaware limited liability company, and Ricerca Holdings, Inc., a Delaware corporation. Ronald Ian Lennox (“Lennox”), Chairman and CEO of Ricerca, is also a defendant in the case.
Most of the opinion focuses on Eurofins’ claims against Ricerca related to specific provisions of the SAPA, whether Ricerca breached these provisions, and whether the breaches of contract were also fraudulent. The Court dismissed many of Eurofins’ claims against Ricerca. All claims against Lennox, aside from those based on the relationship with AstraZeneca PLC (“AZ”), were also dismissed.